MENU
+Compare
ANNX
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$2.81
Change
-$0.02 (-0.71%)
Capitalization
299.53M

ANNX Annexon Forecast, Technical & Fundamental Analysis

a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain

Industry Biotechnology
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ANNX with price predictions
Feb 21, 2025

ANNX in +2.33% Uptrend, advancing for three consecutive days on February 14, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ANNX advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ANNX entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.903) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). ANNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (251.221).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ANNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ANNX is expected to report earnings to rise 7.32% to -26 cents per share on March 20

Annexon ANNX Stock Earnings Reports
Q4'24
Est.
$-0.27
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.23
Q1'24
Beat
by $0.13
Q4'23
Beat
by $0.09
The last earnings report on November 14 showed earnings per share of -25 cents, beating the estimate of -25 cents. With 578.11K shares outstanding, the current market capitalization sits at 299.53M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1400 Sierra Point Parkway
Phone
+1 650 822-5500
Employees
71
Web
https://www.annexonbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CBEAX10.35-0.12
-1.15%
Allspring Large Cap Value CL A
HNLVX22.11-0.28
-1.25%
Harbor Large Cap Value Retirement
PRPQX6.51-0.11
-1.66%
PGIM Jennison Energy Infrastructure R6
ITHRX50.62-0.94
-1.82%
Hartford Capital Appreciation R3
BKPSX55.37-1.93
-3.37%
ProFunds Banks UltraSector Svc

ANNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with FULC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then FULC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANNX
1D Price
Change %
ANNX100%
-0.71%
FULC - ANNX
40%
Loosely correlated
N/A
DNTH - ANNX
37%
Loosely correlated
-0.13%
TRDA - ANNX
37%
Loosely correlated
-0.23%
TCRX - ANNX
36%
Loosely correlated
-0.91%
ERAS - ANNX
36%
Loosely correlated
-3.42%
More